AGRX Stock Earnings: Agile Therapeutics Misses EPS, Misses Revenue for Q4 2023

Source: iQoncept / Shutterstock

Agile Therapeutics (NASDAQ:AGRX) just reported results for the fourth quarter of 2023.

Agile Therapeutics reported earnings per share of -$1.46. This was below the analyst estimate for EPS of -92 cents.
The company reported revenue of $3.62 million.
This was 11.18% worse than the analyst estimate for revenue of $4.07 million.

InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com.

Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/03/agrx-stock-earnings-agile-therapeutics-for-q4-of-2023/.

Source link

About Us

Categories

AGRX Stock Earnings: Agile Therapeutics Misses EPS, Misses Revenue for Q4 2023

Leave a Reply Cancel reply

Categories

Recent Posts

TSLA Stock Alert: Cathie Wood Is Pounding the Table on a $2,000 Tesla Price Target

Western boot sales on the rise since ‘Cowboy Carter’ launch

About Us

Categories

Follow Us

AGRX Stock Earnings: Agile Therapeutics Misses EPS, Misses Revenue for Q4 2023

Share This Post:

Leave a Reply Cancel reply

Related Post